These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 39006029)

  • 21. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
    Leon-Ferre RA; Whitaker KR; Suman VJ; Hoskin T; Giridhar KV; Moore RM; Al-Jarrad A; McLaughlin SA; Northfelt DW; Hunt KN; Conners AL; Moyer A; Carter JM; Kalari K; Weinshilboum R; Wang L; Ingle JN; Knutson KL; Ansell SM; Boughey JC; Goetz MP; Villasboas JC
    Breast Cancer Res; 2024 Jun; 26(1):97. PubMed ID: 38858721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-1BB-Enhanced Expansion of CD8
    Harao M; Forget MA; Roszik J; Gao H; Babiera GV; Krishnamurthy S; Chacon JA; Li S; Mittendorf EA; DeSnyder SM; Rockwood KF; Bernatchez C; Ueno NT; Radvanyi LG; Vence L; Haymaker C; Reuben JM
    Cancer Immunol Res; 2017 Jun; 5(6):439-445. PubMed ID: 28473315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation of tumor-resident CD8
    Corgnac S; Lecluse Y; Mami-Chouaib F
    STAR Protoc; 2021 Mar; 2(1):100267. PubMed ID: 33490983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonality, Antigen Recognition, and Suppression of CD8
    Hammerl D; Massink MPG; Smid M; van Deurzen CHM; Meijers-Heijboer HEJ; Waisfisz Q; Debets R; Martens JWM
    Clin Cancer Res; 2020 Jan; 26(2):505-517. PubMed ID: 31649042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD103
    Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
    Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
    Ali HR; Provenzano E; Dawson SJ; Blows FM; Liu B; Shah M; Earl HM; Poole CJ; Hiller L; Dunn JA; Bowden SJ; Twelves C; Bartlett JM; Mahmoud SM; Rakha E; Ellis IO; Liu S; Gao D; Nielsen TO; Pharoah PD; Caldas C
    Ann Oncol; 2014 Aug; 25(8):1536-43. PubMed ID: 24915873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
    Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
    Sivaganesh V; Promi N; Maher S; Peethambaran B
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue-Resident Memory T Cells in Cancer Immunosurveillance.
    Park SL; Gebhardt T; Mackay LK
    Trends Immunol; 2019 Aug; 40(8):735-747. PubMed ID: 31255505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.
    Goff SL; Danforth DN
    Clin Breast Cancer; 2021 Feb; 21(1):e63-e73. PubMed ID: 32893093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
    Paret C; Simon P; Vormbrock K; Bender C; Kölsch A; Breitkreuz A; Yildiz Ö; Omokoko T; Hubich-Rau S; Hartmann C; Häcker S; Wagner M; Roldan DB; Selmi A; Türeci Ö; Sahin U
    Oncotarget; 2015 Sep; 6(28):25356-67. PubMed ID: 26327325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resident memory T cells and cancer.
    Gavil NV; Cheng K; Masopust D
    Immunity; 2024 Aug; 57(8):1734-1751. PubMed ID: 39142275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.